DNM1L and ovarian cancer: Hypoxia promotes mitochondrial fission and cisplatin resistance in ovarian cancer cells via ROS; consistently, suppression of mitochondrial fission by Mdivi-1, a putative DRP1 inhibitor, or DRP1 silencing enhanced the cisplatin sensitivity of hypoxic ovarian cancer cells.